Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 3, 2007, Pages 365-372

  Blach Olszewska, Zofia ^a   Leszek, Jerzy ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Deficiency of innate immunity; Innate immune reactions; Neurodegenerative disorders; Over stimulation; Regulation system

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; CELL ADHESION MOLECULE; CHEMOKINE; COLOSTRININ; CYTOKINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 6; LECTIN; MONOAMINE OXIDASE INHIBITOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPEPTIDE; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; MICROGLIA; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 34547678667     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Agteresch HJ, Dagnelie PC, van der Gaast A, et al. 2000. Randomized clinical trial of adenosine 5″-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 92:321-328.
2. Aisen PS, Schafer KA, Grundman M, et al. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial 2003. JAMA, 289:2819-2826.
3. Akiyama H, Barger S, Barnum S. 2000. inflammation and Alzheimer's disease. Neurobiol Aging, 21:383-421.
4. Anekonda TS, Reddy PH. 2005. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res Brain Res Rev, 50:361-376.
5. Antonieli L, Fornai M, Colucci R, et al. 2006. A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of expenmental colitis. Inflamm Bowel Dis, 12:117-122.
6. Baccala R, Kono DH, Theofilopoulos AN. 2005. Interferons as pathogenic effectors in autoimmunity. Immunol Rev, 204:9-26.
7. Bate C, Kempster S, Williams A. 2006. Prostaglandin D mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Neuropharmacology, 50:229-237.
8. Błach-Olszewska Z, Zaczyńska E, Kiełbiñski M, et al. 2005. Deficiency of innate immunity of leukocytes is associated with the failure of the induction of remission and survival time in patients with acute leukemia. Polish J Environmental Studies, 14(Suppl. II):36-40.
9. Błach-Olszewska Z. 2005. Innate Immunity: cells, receptors, and signaling pathways. Arch Immunol Ther Ex, 53:245-253.
10. Błais V, Rivest S. 2003. Role of the innate immune response in the brain. Med Sci (Paris), 19:981-987.
11. Camenisch TD, Koller BH, Earp HS, et al. 1999. A novel receptor tyrosine kinase, Mer, inhibits TNF alpha production and lipopolysaccharide-induced endotoxic shock. J Immunol, 162:3498-3503.
12. Caryannopoulos Ln, Yokoyama WN. 2004. Recognition of infected cells by natural killer cells. Curr Op Immunol, 16:26-33.
13. Cembrzyńska-Nowak M, Liebhart J, Bieńkowska-Haba M, et al. 2005. Overproduction of nitric oxide associated with neutrophilic predominance relevant to airway mycotic infections in asthmatics undergoing prolonged glucocorticoid treatment. Cell Biol Mol Lett, 10:677-687.
14. Chang TL. Vargas Jr. Del Portillo A, et al. 2005. Dual role of α-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest, 115:765-776.
15. Cohen PL, Caricchio R, Abraham V, et al. 2002. Delayed apoptic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med, 196:135-140.
16. Dik MG, Jonker C, Hack CE, et al. 2005. Serum inflammatory proteins and cognitive decline in older persons. Neurology, 64:1371-1377.
17. Dziedzic T. 2006. Systemic inflammatory markers and risk of dementia. Am J Alzheimers Dis Other Demen, 21:258-262.
18. Elliott J, Johnston JA. 2004. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol, 25:434-440.
19. Elson CO, Cong Y, McCracken VJ, et al. 2005. Experimental model of inflammatory bowel disease reveal innate, adaptive and regulatory mechanisms of host dialogue with the microbiota. Immunological Rev, 206:260-276.
20. Ferlazzo G, Munz C. 2004. NK cell compartments and their activation by dendritic cells. J Immunol, 172:1333-1339.
21. Fiala M, Lin J, Ringman J, et al. 2005. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis, 7:221-232.
22. Fujita T, Matsushita M, Endo Y. 2004. The lectin-complement pathway - its role in innate immunity and evolution. Immunol Rev, 198:185-202.
23. Gasiorowski K, Leszek J. 1997. A proposed new strategy of immunotherapy for Alzheimer's disease. Medical Hypotheses, 49:319-326.
24. Gerlach M, Double KL, Youdim MB, et al. 2000. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox Res, 2:99-114.
25. Godbout JP, Chen J, Abraham J, et al. 2005. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J, 19:1329-1331.
26. Hasko G, Cronstein BN. 2004. Adenosine: an endogenous regulator of innate immunity. Trends Immunol, 25:33-39.
27. Jijon HB, Walker J, Hoentien F, et al. 2005. Adenosine is negative regulator of NFκB and MAPK signaling in human intestinal epithelial cells. Cell Immunol, 237:86-95.
28. Johnson GB, Brunn GJ, Platt JL. 2003. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol, 23:15-44.
29. Jung DY, Lee H, Jung BY, et al. 2005. TLR4 but not TLR2, signals autoregulatory apoptosis of cultured microglia: a critical role of IFNβ as a decision marker. J Immunol, 174:6467-6476.
30. Kovarik A, Fojtova M, Boudny V, et al. 2005. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res, 15:481-488.
31. Kreckler LM, Wan TC, Ge ZD, et al. 2006. Adenosine inhibits TNF alpha release from mouse peritoneal macrophages via A2A and A2B, but not A3 adenosine receptors. J Pharmacol Exp Ther, 317:172-180.
32. Ku CL, Yang K, Bustamate J, et al. 2005. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunological Rev, 203:10-20.
33. Kukar T, Murphy MP, Eriksen JK, et al. 2005. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta 42 production. Natl Med, 11:545-550.
34. Lang R, Patel D, Morris JJ, et al. 2002. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol, 169:2253-2263.
35. LeBourder E, Rey-Nores JE, Rushmere NK, et al. 2003. Soluble forms of toll-like receptor (TLR) 2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol, 171:6680-6689.
36. Lee JY, Jhun BS, Oh YT, et al. 2006. Activation of adenosine A (3) receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of P13-kinase/Akt and NF-kappa B activation in murine BV2 microglial cells. Neurosci Lett, 396:1-6.
37. Lehnardt S, Massillon L, Follett P, et al. 2003. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. PNAS, 100:8514-19.
38. Leszek J, Basinski T, Kiejna A, et al. 2004. Donepezil protects monocytes from Beta-amyloid-induced death. Neurobiol Aging, P3-281.
39. Leszek J, Inglot AD, Janusz M, et al. 1999. Colostrinin®:a Proline-Rich Polypeptide(PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp, 4:377-385.
40. Leszek J, Inglot ADS, Janusz M, et al. 2002. Colostrinin® praline-rich polypeptide complex from ovine colostrums- a long-term study of its efficacy in Alzheimer's disease. Med Sci Monit, 8:PI93-PI96.
41. Liberatore GT, Jackson-Levis Y, Vukosavic S, et al. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in MTPT model of Parkinson disease. Nat Med, 5:1403-1409.
42. Lighvani S, Huang X, Trivedi PP, et al. 2005. Substance P regulates natural killer cell interferon γ production and resistance to Pseudomonas aeruginosa infection. Eur J Immunol, 35:1567-1575.
43. Lu J, Teh C, Kishore U, et al. 2002. Collectins and ficolins: sugar pattern recognition molecules of the mammalian innate immune system. Biochim Biophys Acta, 1572:387-400.
44. Lu Q, Lemke G. 2001. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science, 293:306-311.
45. Malm T, Koistinaho M, Parepalo M, et al. 2005. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis, 18:134-142.
46. Mansell A, Smith F, Doyle SL, et al. 2006. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol, 7:148-155.
47. Marchetti B, Abbraacchio MP. 2005. To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci, 26:517-525.
48. McRae A, Dahlstrom A, Polinsky R. 1993. Cerebrospinalis fluid microglial antibodies:potential diagnostic markers for immune mechanisms in Alzheimer's disease. Behav Brain Res, 57:225-234.
49. Moisse K, Strong MJ. 2006. Innate immunity in amyotrophic lateral sclerosis. Biochim Biophys Acta, 1762:1083-1093.
50. Nagele RG, Wegiel J, Venkataraman V, et al. 2004. Contribution of glial cells to the development of amyloid plaque in Alzheimer's disease. Neurobiol Aging, 25:663-674.
51. 2B receptor-mediated post-transcriptional mechanism. J Immunol, 175:8260-8270.
52. Nijhuis E, Hinloopen B, Van Duijn C. 1994. Decreased sensitivity to dexamethasone in lymphocytes from patients with Alzheimer's disease. Clin Immunol Immunopathol, 73:45-52.
53. Orzechowska B, Antoszków Z, Błach-Olszewska Z. 2003. Individual differentiation of innate antiviral immunity in humans; role of endogenous interferons and tumor necrosis factor in immunity of leukocytes. Arch Immunol Ther Exp, 51:51-60.
54. Paradowska E, Błach-Olszewska Z, Sender J, et al. 1996. Antiviral nonspecific immunity of human placenta at term; possible role of endogenous tumor necrosis factors and interferons. J Interferon Cytokines Res, 16:941-948.
55. Poea-Guyon S, Christadoss P, LePanse R, et al. 2005. Effects of cytokines on acetylocholine receptor expression: implications for myasthenia gravis. J Immunol, 174:5941-5949.
56. Prieto AL, Weber JL, Lai C. 2000. Expression of the receptor protein-tyrosine kinases Tyro-3, Axl, and met in the developing rat central nervous system. J Com Neurol, 425:295-314.
57. Qasitni P, Ming-Lum A, Ghanipour A, et al. 2006. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumour necrosis factor alpha and nitric oxide production by macrophages. J Biol Chem, 281:6316-6324.
58. Rifkin IR, Leadbetter EA, Busconi L, et al. 2005. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunological Rev, 204:27-42.
59. Rogers J, Lue IF. 2001. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Tnt, 39:333-340.
60. Rogers J. 1995. Inflammation as a pathogenic mechanism in Alzheimer's disease. Drug Res, 45:439-442.
61. Rybka K, Orzechowska B, Siemieniec I, et al. 2003. Age-related natural antiviral non-specific immunity of human leukocytes. Med Sci Monit, 9:BR413-417.
62. Scott RS, McMahon EJ, Pop SM, et al. 2001. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature, 411:207-211.
63. Simard AR, Rivest S. 2005. Do pathogen exposure and innate immunity cause brain diseases? Neurol Res, 27:717-725.
64. Simard AR, Rivest S. 2006. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry, 11:327-335.
65. Simard AR, Soulet D, Gowing G, et al. 2006. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer disease. Neuron, 49:489-502.
66. Stark JL, Cross AH. 2006. Differential expression of suppressors of cytokine signaling-1 and -3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis. Int Immunol, 18:347-353.
67. Stolzing A, Grune T. 2004. Neuronal apoptotic bodies: phagocytosis and degradation by primary microglial cells. FASEB J, 18:743-745.
68. Strieter RM, Keane MP. 2004. Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J Clin Invest, 114:165-168.
69. Swennen ELR, Bast A, Dagnelie PC. 2005. Immunoregulatory effect of adenosinetriphophate on cytokine release from stimulated whole blood. Eur J Immunol, 35:852-858.
70. Takase H, Yu CR, Liu X, et al. 2005. Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uvenitis (EAU): potential neuroprotective role of SOCS proteins. J Neuroimmunol, 168:118-127.
71. Takatori Y. 2006. Mechanisms of neuroprotective effects of therapeutic acetylocholine inhibitors used in treatment of Alzheimer's disease. Yakugaku Zasshi, 126:607-616.
72. Tanga FY, McMenemy NN, DeLeo JA. 2005. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. PNAS, 102:5856-5861.
73. Togo T, Akiyama H, Iseki E, et al. 2002, Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol, 124:83-92.
74. Townsend KP, Town T, Mori T, et al. 2005. CD40 signaling regulates innate and adaptive activation in response to amyloid β-peptide. Eur J Immunol, 35:901-910.
75. Walker DG, Link J, Lue LF, et al. 2006. Gene expression changes by amyloid, beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol, 79:596-610.
76. Walker DG, Link J, Lue LF, et al. 2006. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory. J Leukoc Biol, 79:596-610.
77. Wang H, Chen Y, Ge Y, et al. 2005. Immunoexpression of Tyro 3 family receptors - Tyro 3, Axl, and Mer - and their ligand Gas in postnatal developing mouse testis. J Histochem Cytochem, 53:1355-1364.
78. Wenk GL. 2003. Inflammation in Alzheimer's disease: its role and an opportunity for therapy. Brain Aging, 3:16-20.
79. Wong CC, Lee WM. 2002. The proximal cis-acting elements Sp1, Sp3 and E2F regulate mouse mer gene transcription in Sertoli cells. Eur J Biochem, 269:3789-3800.
80. Wyss-Coray T. 2006. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med, 12:1005-1015.
81. Yip AG, Green RC, Huuyck M, et al. 2005. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk:the MIRAGE Study. BMC Geriatr, 5:2.
82. Yoshimura A. 2005. Negative regulation of cytokine signaling. Clin Rev Allergy Immunol, 28:205-220.
83. Zaczyńska E, Błach-Olszewska Z, Gejdel E. 1995. Production of cytokines with antiviral activity by endothelial cells. J Intreferon Cytokines Res, 15:811-814.
84. Zaidi SI, Jafri A, Martin RJ, et al. 2006. Adenosine A (2A) receptors are expressed by GABAergic neurons of medulla oblongata in developing rat. Brain Res, 1071:42-53.
85. Zitvogel L. 2002. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med, 195:F9-F14.